Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan-Reference-Cited by-同舟云学术

Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan

Published:2021-01 Issue:1 Volume:120 Page:542-550
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Yang Chih-Chao^ORCID,Ro Long-Sun,Tsai Nai-Wen,Lin Chou-Ching,Huang Wen-Nan,Tsai Ching-Piao,Lin Thy-Sheng,Su Jen-Jen,Huang Chin-Chang,Lyu Rong-Kuo,Chen Hsin-Hua,Lee Wei-Ju,Chen Po-Lin,Yang Audrey

Funder

Novartis (Taiwan) Co., Ltd

Publisher

Elsevier BV

Subject

General Medicine

Reference40 articles.

1. Multiple sclerosis patients and clinical care in Taiwan;Cheng;Neurol Res,2013

2. Multiple sclerosis in the Asia Pacific region: a systematic review of a neglected neurological disease;Cheong;Front Neurol,2018

3. Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets;Ip;J Neuroimmunol,2018

4. Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients;Liao;BMC Neurol,2014

5. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines;Goodin;Neurology,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis;Cureus;2023-09-18

2. The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary;PLOS ONE;2022-04-22

3. Thematic analysis of multiple sclerosis research by enhanced strategic diagram;Multiple Sclerosis Journal;2022-02-15

4. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry;PLOS ONE;2021-10-13

5. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review;Expert Opinion on Drug Safety;2021-04-21